Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV

A. Sidney Barritt, Ravi Jhaveri*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Purpose of Review: Increasing hepatitis C virus (HCV) cases over the past decade have raised concerns about subsequent increased cases in infants due to mother to child transmission (MTCT). Many are reminded of the early days of HIV and the rationale for using antiretroviral agents during pregnancy. Recent Findings: Direct-acting antivirals (DAAs) that are highly potent, all-oral, short-duration regimens that cure HCV have led many to consider what it would entail to use DAAs for pregnant women. Considering HIV and Hepatitis B virus (HBV) as two infections with MTCT to draw lessons from, DAA use to interrupt HCV MTCT comes with risks, costs, and many potential benefits. Summary: When considering how to effectively curb the current epidemic of HCV in the US population, using DAAs to treat pregnant women with HCV offers potential benefits to the mother immediately, to the pair in the short-term and to the child, family, and society over a lifetime.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalCurrent HIV/AIDS Reports
Issue number2
StatePublished - Apr 1 2018


  • Hepatitis C
  • Mother to children transmission
  • Pregnancy
  • Vertical transmission

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases


Dive into the research topics of 'Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV'. Together they form a unique fingerprint.

Cite this